Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Trial to Evaluate Safety and Immunogenicity of a Next-generation COVID-19 Vaccine Delivered by Inhaled Aerosol to Humans

NCT06381739 is registered in ClinicalTrials.gov with McMaster University as lead sponsor.

NCT NCT06381739
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06381739 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Trial to Evaluate Safety and Immunogenicity of a Next-generation COVID-19 Vaccine Delivered by Inhaled Aerosol to Humans
Lead sponsor
McMaster University
Phase
Phase 2
Overall status
Recruiting
Start date
March 25, 2025
Completion date
January 31, 2027
Enrollment
350 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

covid-19 infection